title: Strategy for the prevention and treatment of chronic lung disease of the premature infant.
abstract: Based on the analyses of approximately 1,000 infants with CLD, this condition was classified into 7 types according to the preceding illnesses and the chest X-ray appearance. The profile of inflammatory enzymes, cytokines and chemical mediators supported the relevance of the classification. Since different insults to the lung with different onsets exhibit the different spectra of the disease, appropriate strategies adapted to each type of CLD should be pursued. For types I and II prophylactic administration of exogenous surfactant, early enough to prevent the oxygen toxicity and barotrauma, is important. RDS can be diagnosed by the stable microbubble rating on gastric aspirates within several minutes of birth. The application of milder modes of ventilation such as HFOV started at birth should also be remembered. The recommended strategies for type IV and V are the care of the very low birth weight infant in the fully humidified incubator with careful fluid administration to prevent symptomatic PDA, and early detection and treatment of infection by screening with sensitive methods such as the APR score. However, the most difficult problem is to identify the correct strategy for type III and III', because these types of CLD can only be prevented by the complete eradication of intrauterine infection.
authors: Department of Pediatrics, Saitama Medical Center, Saitama Medical School, Kawagoe, Japan. yjogawa@saitama-med.ac.jp
authors: Y
authors: Y
authors: Ogawa
authors: H
authors: H
authors: Shimizu
authors: J
authors: J
authors: Takasaki
authors: T
authors: T
authors: Nakamura
mesh_terms: D002908:Chronic Disease; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000517:prevention & control / Q000628:therapy*; D008171:Lung Diseases / Q000145:classification / Q000517:prevention & control / Q000628:therapy*; D011663:Pulmonary Surfactants / Q000627:therapeutic use; D012127:Respiratory Distress Syndrome, Newborn / Q000628:therapy
chemical_list: D011663:Pulmonary Surfactants